| | | | | | | | | | |
|
|
| Dockets Entered
On December 6, 2004
Table of Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1976N-0052N
|
| OTC Nasal Decongestants
|
|
|
| 1979P-0484
|
| MEMO RE "PAPER NDA'S"
|
|
|
| 1990P-0201
|
| Optimum size & Style of print to be used to label OTC Drugs
|
|
|
| 1993N-0195
|
| Safe Processing & Importing of Fish & Fishery Products
|
|
|
| 1995N-0259
|
| Over the Counter Drug Labeling; Public Hearing
|
|
|
| 1996N-0420
|
| OTC Human Drugs; Proposed Labeling Requirements
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
| 1998N-0337
|
| Over the counter human drugs labeling requirements
|
|
|
| 2000N-0504
|
| Egg Safety Action Plan
|
|
|
| 2002N-0291
|
| Proposal to Debar Baldev Raj Bhutani;Notice of Opportunity
|
|
|
| 2002N-0434
|
| Withdrawal of Certain Proposed rules & other propose action
|
|
|
| 2003D-0112
|
| Independent Consultants for Biotechnology Clinical Trias
|
|
|
| 2003N-0059
|
| Pharmaceutical cGMPs for 21st Century: A Risk-Based Approach
|
|
|
| 2003P-0365
|
| Galderma product, solage containing 2% Mequinol, and 0.01% tretinoin, NDA 20-922 can be formulated as a topical solution with the substitution of Hydroquinone at 4% for the 2% mequinol as an ANDA
|
|
|
|
|
|
| 2003P-0414
|
| Hydrocondone Bitartrate and Acetaminophen tablets 5 mg/300 mg as an ANDA
|
|
|
| 2004D-0343
|
| Hospital Bed System Dimensional Guidance to Reduce Entrapment
|
|
|
| 2004D-0493
|
| Draft Guidance for Industry on Recommended Approaches to Integration of Genetic Toxicology Study Results
|
|
|
| 2004D-0509
|
| Guidance and Protocol for Industry and Food and Drug Administration Staff: Certification of Fish and Fishery Products for Export to the European Union and the European Free Trade Association
|
|
|
| 2004D-0510
|
| Proposed Referral Program from the Food and Drug Administration to the National Oceanic and Atmospheric Administration Seafood Inspection Program for the Certification of Live and Perishable Fish and
|
|
|
|
|
|
| 2004N-0062
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Color Additive Certification Requests and Recordkeeping
|
|
|
| 2004N-0416
|
| Beverages: Bottled Water
|
|
|
| 2004N-0516
|
| Agency Information Collection Activities: Proposed Collection; Comment Request; 2005 Food Safety Survey
|
|
|
| 2004P-0141
|
| NDA 19-443 Sodium Bicarbonate Injection in PET Abboject Vials was not withdrawn for safety or effectiveness reasons
|
|
|
| 2004P-0202
|
| Notify State & Federal regulators of GRAS requirements of milk protein Concentrate
|
|
|
| 2004P-0298
|
| Nutrient Content Claims for the Carbohydrate Content of Food
|
|
|
| 2004P-0299
|
| Nutrient Content Claims for Carbohydrates
|
|
|
| 2004P-0324
|
| ANDA filed by Ivax Pharmaceuticals for a generic formulation of DuoNeb subject to a 30-month stay of approval
|
|
|
| 2004P-0339
|
| Refuse to file an ANDA for the combination drug amlodipine besylate-benazepril hydrochloride (amlodipine-benazepril)
|
|
|
| 2004Q-0083
|
| Qualified health claim (QHC): Green Tea and Reduced Risk of Cancer
|
|
|
| 2004V-0537
|
| Projector for a Laser Light Show
|
|
|
| 1976N-0052N
|
| OTC Nasal Decongestants
|
|
|
| BKG
3
|
| Background Material
|
| Vol #:
|
| 77
|
|
|
| GDL
1
|
| Guidance
|
| Vol #:
|
| 77
|
|
|
| 1979P-0484
|
| MEMO RE "PAPER NDA'S"
|
|
| | | | | | | | |
|
|
| ACK 3
|
| HFA-305 to Alan Kaplan
|
| Vol #:
|
| 1
|
|
|
| 1990P-0201
|
| Optimum size & Style of print to be used to label OTC Drugs
|
|
|
| C
83
|
| Cosmetic, Toiletry, and Fragrance Assn (CFTA)
|
| Vol #:
|
| 8
|
|
|
| 1993N-0195
|
| Safe Processing & Importing of Fish & Fishery Products
|
|
|
| BKG 2
|
| Background Material
|
| Vol #:
|
| 2
|
|
|
| 1995N-0259
|
| Over the Counter Drug Labeling; Public Hearing
|
|
|
| C
29
|
| Cosmetic, Toiletry, and Fragrance Assn (CTFA)
|
| Vol #:
|
| 13
|
|
|
| 1996N-0420
|
| OTC Human Drugs; Proposed Labeling Requirements
|
|
|
| C
1035
|
| Cosmetic, Toiletry, and Fragrance Assn (CTFA)
|
| Vol #:
|
| 25
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
| LET
14941
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14942
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14943
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14944
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14945
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14946
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14947
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14948
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14949
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14950
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14951
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14952
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14953
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14954
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14955
|
| Leiner Health Products
|
| Vol #:
|
| 132
|
|
|
| LET
14956
|
| Lleiner Health Products
|
| Vol #:
|
| 132
|
|
|
| 1998N-0337
|
| Over the counter human drugs labeling requirements
|
|
|
| C
16
|
| Cosmetic, Toiletry, and Fragrance Assn (CTFA)
|
| Vol #:
|
| 9
|
|
|
| 2000N-0504
|
| Egg Safety Action Plan
|
|
|
| C 148
|
| M. Mulligan
|
| Vol #:
|
| 10
|
|
|
| C 149
|
| I. Mills
|
| Vol #:
|
| 10
|
|
|
| C 150
|
| K. Green
|
| Vol #:
|
| 10
|
|
| | | | | | | | |
|
|
| C
151
|
| Monty Produce Co.
|
| Vol #:
|
| 10
|
|
|
| C 152
|
| P. Dasgupta
|
| Vol #:
|
| 10
|
|
|
| C 153
|
| T. Siegrist
|
| Vol #:
|
| 10
|
|
|
| C
154
|
| Galivants Ferry Farms Corporation
|
| Vol #:
|
| 10
|
|
|
| C 155
|
| L. Allen
|
| Vol #:
|
| 10
|
|
|
| C
156
|
| Global Poultry Marketing ServicesGilman T. Dedrick
|
| Vol #:
|
| 10
|
|
|
| C 157
|
| C. McCardell
|
| Vol #:
|
| 10
|
|
|
| 2002N-0291
|
| Proposal to Debar Baldev Raj Bhutani;Notice of Opportunity
|
|
|
| ND
1
|
| FDA
|
| Vol #:
|
| 4
|
|
|
| 2002N-0434
|
| Withdrawal of Certain Proposed rules & other propose action
|
|
|
| NWL
1
|
| FDA
|
| Vol #:
|
| 3
|
|
|
| 2003D-0112
|
| Independent Consultants for Biotechnology Clinical Trias
|
|
|
| CR 1
|
| M. Van Hoef, MD, Ph.D., MBA
|
| Vol #:
|
| 1
|
|
|
| 2003N-0059
|
| Pharmaceutical cGMPs for 21st Century: A Risk-Based Approach
|
|
|
| C
7
|
| Pfizer, Inc.
|
| Vol #:
|
| 13
|
|
|
| 2003P-0365
|
| Galderma product, solage containing 2% Mequinol, and 0.01% tretinoin, NDA 20-922 can be formulated as a topical solution with the substitution of Hydroquinone at 4% for the 2% mequinol as an ANDA
|
|
|
|
|
|
|
| PDN
2
|
| HFD-600 to Jerussi Consulting, Inc.
|
| Vol #:
|
| 1
|
|
|
| 2003P-0414
|
| Hydrocondone Bitartrate and Acetaminophen tablets 5 mg/300 mg as an ANDA
|
|
|
| PAV
1
|
| HFD-600 to Lachman Consultant Services, Inc
|
| Vol #:
|
| 1
|
|
|
| 2004D-0343
|
| Hospital Bed System Dimensional Guidance to Reduce Entrapment
|
|
|
| C
9
|
| American Assn of Homes and Services for the Aging (AAHSA)
|
| Vol #:
|
| 1
|
|
|
| C
10
|
| St. Joseph Mercy Health Center
|
| Vol #:
|
| 1
|
|
|
| C
11
|
| Beaumont Services Company, LLC
|
| Vol #:
|
| 1
|
|
|
| 2004D-0493
|
| Draft Guidance for Industry on Recommended Approaches to Integration of Genetic Toxicology Study Results
|
|
|
| GDL
1
|
| Guidelines
|
| Vol #:
|
| 1
|
|
|
| NAD
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2004D-0509
|
| Guidance and Protocol for Industry and Food and Drug Administration Staff: Certification of Fish and Fishery Products for Export to the European Union and the European Free Trade Association
|
|
|
|
|
|
| GDL
1
|
| GUIDANCE
|
| Vol #:
|
| 1
|
|
|
| NAD
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2004D-0510
|
| Proposed Referral Program from the Food and Drug Administration to the National Oceanic and Atmospheric Administration Seafood Inspection Program for the Certification of Live
|
|
| | | | | | | | |
|
|
| and Perishable Fish and
|
|
|
| GDL
1
|
| GUIDANCE
|
| Vol #:
|
| 1
|
|
|
| NAD
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2004N-0062
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Color Additive Certification Requests and Recordkeeping
|
|
|
| NAL
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| SS
1
|
| Supporting Statement
|
| Vol #:
|
| 1
|
|
|
| 2004N-0416
|
| Beverages: Bottled Water
|
|
|
| BKG
1
References
|
| Quality Standard Regulation for Arsenic in Bottled Water
|
| Vol #:
|
| 1
|
|
|
| NPR
1
|
| FDA
|
| Vol #:
|
| 2
|
|
|
| 2004N-0516
|
| Agency Information Collection Activities: Proposed Collection; Comment Request; 2005 Food Safety Survey
|
|
|
| N
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2004P-0141
|
| NDA 19-443 Sodium Bicarbonate Injection in PET Abboject Vials was not withdrawn for safety or effectiveness reasons
|
|
|
| LET
2
|
| HFD-7 to Abbott Laboratories
|
| Vol #:
|
| 1
|
|
|
| 2004P-0202
|
| Notify State & Federal regulators of GRAS requirements of milk protein Concentrate
|
|
|
| C 10
|
| D. Hall
|
| Vol #:
|
| 1
|
|
|
| 2004P-0298
|
| Nutrient Content Claims for the Carbohydrate Content of Food
|
|
|
| LET
1
|
| Unilever United States Inc
|
| Vol #:
|
| 2
|
|
|
| SUP
3
|
| Unilever United States Inc
|
| Vol #:
|
| 2
|
|
|
| 2004P-0299
|
| Nutrient Content Claims for Carbohydrates
|
|
|
| LET
1
|
| Frito-Lay Inc
|
| Vol #:
|
| 1
|
|
|
| 2004P-0324
|
| ANDA filed by Ivax Pharmaceuticals for a generic formulation of DuoNeb subject to a 30-month stay of approval
|
|
|
| AMD
2
|
| Dey, L.P.
|
| Vol #:
|
| 1
|
|
|
| 2004P-0339
|
| Refuse to file an ANDA for the combination drug amlodipine besylate-benazepril hydrochloride (amlodipine-benazepril)
|
|
|
| C
1
|
| Dr. Reddy's Laboratories (Dr. Reddy's)
|
| Vol #:
|
| 1
|
|
|
| 2004Q-0083
|
| Qualified health claim (QHC): Green Tea and Reduced Risk of Cancer
|
|
|
| ANS
1
|
| HFS-830 to Fleminger, Inc
|
| Vol #:
|
| 8
|
|
|
| LET
3
|
| Fleminger, Inc
|
| Vol #:
|
| 8
|
|
|
| LET
4
|
| Fleminger, Inc
|
| Vol #:
|
| 8
|
|
|
| 2004V-0537
|
| Projector for a Laser Light Show
|
|
|
| ACK
1
|
| HFA-305 to Tribal Existance Productions
|
| Vol #:
|
| 1
|
|